WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation of new preclinical data with the Company's experimental therapies IMGN529

WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that David Johnston , Executive Vice President and Chief Financial Officer, will present at the

WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius , President and CEO, will present at the upcoming 34 th Annual J. P.

WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced recent product program advancements and anticipated 2016 events in advance of the 34 th

WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m.

WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the Company earned a milestone payment with Bayer's initiation of a global Phase 2 clinical

− Conference Call Today at 8:00 am ET − Both ImmunoGen's FORWARD I and FORWARD II clinical trials are open for patient enrollment. FORWARD I is designed to support an Accelerated Approval pathway for lead program mirvetuximab soravtansine and FORWARD II assesses this first-in-class folate receptor

WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be

− ImmunoGen's mirvetuximab soravtansine folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) to be assessed in combination with Merck's anti-PD-1 therapy − WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer

- Successor Expected to be Announced Shortly - WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius , age 63, has decided to